Table 2.
Body weight at the beginning (day 1), middle (day 7) and final (day 15) of the treatment with 100 mg/kg (TV100), 200 mg/kg (TV200) or 400 mg/kg (TV400) of Fr-BuVt
| Day 1 (g) | Day 7 (g) | Day 15 (g) | Weight ratio (%) | |
|---|---|---|---|---|
| CS | 45.35 ± 1.07 | 46.72 ± 1.11 | 47.82 ± 1.31 | + 5.44 |
| TS | 47.01 ± 1.17 | 47.55 ± 1.27 | 44.52 ± 1.08 | − 5.29 |
| TV100 | 46.79 ± 1.00 | 47.14 ± 1.23 | 46.07 ± 1.12 | − 1.53 |
| TV200 | 46.53 ± 1.23 | 48.15 ± 1.14 | 48.99 ± 1.17 | + 5.28 |
| TV400 | 47.93 ± 1.4 | 49.13 ± 1.39 | 50.09 ± 1.49 | + 4.5 |
CS (Control animals treated with saline; TS (Ehrlich carcinoma-bearing mice treated with saline); TV100 (Ehrlich carcinoma-bearing mice treated with 100 mg/kg Fr-BuVt); TV200 (Ehrlich carcinoma-bearing mice treated with 200 mg/kg Fr-BuVt); TV400 (Ehrlich carcinoma-bearing mice treated with 400 mg/kg Fr-BuVt). Values are expressed as means ± SEM. There are no significative differences between groups in the same day, one-way ANOVA followed by Holm-Sidak post hoc test.